If this message does not display properly, please click here to launch your browser
|
— A Webinar from Decision Resources |
|||
Based on our European Physician & Payer Forum report entitled Will Emerging Monoclonal Antibodies Threaten MabThera’s Domination of the Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Markets in Europe? Clinician and Payer Perspectives, Decision Resources is offering an exclusive webinar entitled European Clinician and Payer Perspectives on the Dominance of Roche’s MabThera in NHL and CLL – Will Emerging Monoclonal Antibodies Be Able to Compete? Because this webinar will feature major findings, it is ONLY available to purchasers of this report. Please contact us to learn how you can purchase this European Physician & Payer Forum report and attend the webinar. The current treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) is characterized by the high uptake of Roche’s MabThera (rituximab). MabThera, an anti-CD20 monoclonal antibody (MAb), has been approved in multiple NHL patient populations and across various lines of treatment. Based on the dramatic clinical and commercial success of MabThera, there is considerable incentive in developing similar MAbs for the treatment of NHL and CLL. Emerging MAbs hoping to enter the NHL and CLL drug-treatable populations face formidable competition from the well-established MabThera and significant penetration into lucrative patient settings is highly challenging. Furthermore, MabThera and emerging MAbs will be threatened by the imminent expected launch of biosimilar versions of rituximab in Europe. GlaxoSmithKline/Genmab’s Arzerra (ofatumumab) recently received conditional marketing authorization for the treatment of heavily refractory CLL patients and therefore presents the most immediate threat to MabThera’s dominance. Hematologist-oncologists and payers will be forced to consider emerging MAbs and biosimilar rituximab for NHL and CLL over the next several years – ultimately leading to changes in clinical practice in increasingly cost-conscious markets. Decision Resources surveyed 251 European hematologist-oncologists and interviewed 15 European Payers to assess their attitudes and expectations surrounding current and emerging MAbs for NHL and CLL. This webinar, presented by Decision Resources Analyst Andrew Merron, Ph.D. will answer the following questions:
Dr. Merron will conduct a live Q & A session after the presentation. Registration European Clinician and Payer Perspectives on the Dominance of Roche’s MabThera in NHL and CLL – Will Emerging Monoclonal Antibodies Be Able to Compete? September 22, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Physician & Payer Forum report and attend the webinar, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
Andrew Merron, Ph.D., is a senior oncology analyst at Decision Resources. Dr Merron’s research interests and areas of expertise cover hematological malignancies (including lymphoma, leukemia and myeloma) and prostate cancer. Dr. Merron received his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses. Prior to obtaining his Ph.D., he earned his B.Sc. in biochemistry from the University of Bath.